Allogene Therapeutics, Inc. (ALLO)

NMS – Real Time Price. Currency in USD

2.06

-0.06 (-2.69%)

Market open: Aug 12, 2026, 3:50 PM EDT

2.15

+0.03 (1.42%)

Previous after-hours: Aug 11, 2026, 7:51 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

04.08.2026

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

Videos

No Data

There is no data to display

Allogene Therapeutics, Inc. (ALLO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Videos

No Data

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Videos

No Data

Search stocks

Allogene Therapeutics, Inc. (ALLO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Videos

No Data

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Videos

No Data